LobbyingKaneka Pharma America lobbying by quarter
Kaneka Pharma America's latest lobbying report covers Q4 2025, at $40K. The four quarters Q3 2025–Q2 2026 total $70K. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid.
Kaneka Pharma America
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $70K
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $30K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $30K | 1 |
| Q2 2024 | $30K | 1 |
| Q3 2024 | $30K | 1 |
| Q4 2024 | $30K | 1 |
| Q1 2025 | $40K | 1 |
| Q2 2025 | $30K | 1 |
| Q3 2025 | $30K | 1 |
| Q4 2025 | $40K | 1 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Medicare and Medicaid13 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES13 reports
- Centers For Medicare and Medicaid Services (CMS)12 reports
- SENATE9 reports
Firms it paid
| Firm | ||
|---|---|---|
| King & Spalding | $410K | 13 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst.(2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012),Staff Asst. (2010-2011); Energy and Commerce Committee:Staff (2015-2017) | Q4 2025 |
| PREEYA NORONHA PINTO | Deputy GC, Principal Deputy GC, Acting GC, HHS | Q2 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 01/19for Q4 2025 | King & Spalding | $40K |
| 25/10/19for Q3 2025 | King & Spalding | $30K |
| 25/07/21for Q2 2025 | King & Spalding | $30K |
| 25/04/17for Q1 2025 | King & Spalding | $40K |
| 25/01/14for Q4 2024 | King & Spalding | $30K |
| 24/10/19for Q3 2024 | King & Spalding | $30K |
| 24/07/21for Q2 2024 | King & Spalding | $30K |
| 24/04/19for Q1 2024 | King & Spalding | $30K |
| 24/01/15for Q4 2023 | King & Spalding | $30K |
| 23/10/16for Q3 2023 | King & Spalding | $30K |
| 23/07/11for Q2 2023 | King & Spalding | $30K |
| 23/04/17for Q1 2023 | King & Spalding | $30K |
| 23/01/18for Q4 2022 | King & Spalding | $30K |